Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

Wang, Huan; Guo, Jianxin; Wang, Tianze; Wang, Kai; Wu, Zhuojun; Sun, Tianze

doi:10.1136/bmjopen-2021-048975

Cited by 7 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 The evidence suggests that bevacizumab can prolong the progression-free survival (PFS) of patients with glioma within 18 months but can't prolong the OS. 47 Cetuximab and nimotuzumab target epidermal growth factor receptor (EGFR), which can block its ligand activity, induce apoptosis, antiangiogenesis, and thus achieve the effect of inhibiting GBM cells. 48 In a phase II clinical study of cetuximab treated in patients with relapsed GBM, cetuximab did not benefit patients from PFS and OS, regardless of whether accompanied by EGFR amplification.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Oncolytic viral therapy as promising immunotherapy against glioma

Hu,

Tian,

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

Glioma is a common primary central nervous system malignant tumor in clinical, traditional methods such as surgery and chemoradiotherapy are not effective in treatment. Therefore, more effective treatments need to be found. Oncolytic viruses (OVs) are a new type of immunotherapy that selectively infects and kills tumor cells instead of normal cells. OVs can mediate antitumor immune responses through a variety of mechanisms, and have the ability to activate antitumor immune responses, transform the tumor microenvironment from “cold” to “hot,” and enhance the efficacy of immune checkpoint inhibitors. Recently, a large number of preclinical and clinical studies have shown that OVs show great prospects in the treatment of gliomas. In this review, we summarize the current status of glioma therapies with a focus on OVs. First, this article introduces the current status of treatment of glioma and their respective shortcomings. Then, the important progress of OVs of in clinical trials of glioma is summarized. Finally, the urgent challenges of oncolytic virus treatment for glioma are sorted out, and related solutions are proposed. This review will help to further promote the use of OVs in the treatment of glioma.

show abstract

Section: Monoclonal Antibodiesmentioning

confidence: 99%

Oncolytic viral therapy as promising immunotherapy against glioma

Hu,

Tian,

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

show abstract

“…Bevacizumab, which is an antiangiogenic agent by its ability to inhibit VEGF, has also been approved for use in glioblastoma patients (Avastin; FDA approval: 2009 for recurrent glioblastoma). However, trials have shown that treatment with Bevacizumab prolongs progression-free survival, but does not have any significant effect on overall survival [ 175 ].…”

Section: Clinical Targeting Of Glioblastoma: Is There An Anti-invasion/anti-migration Treatment?mentioning

confidence: 99%

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

Seker-Polat

Degirmenci

Solaroğlu

et al. 2022

Cancers

View full text Add to dashboard Cite

Glioblastoma is the most common and malignant primary brain tumor, defined by its highly aggressive nature. Despite the advances in diagnostic and surgical techniques, and the development of novel therapies in the last decade, the prognosis for glioblastoma is still extremely poor. One major factor for the failure of existing therapeutic approaches is the highly invasive nature of glioblastomas. The extreme infiltrating capacity of tumor cells into the brain parenchyma makes complete surgical removal difficult; glioblastomas almost inevitably recur in a more therapy-resistant state, sometimes at distant sites in the brain. Therefore, there are major efforts to understand the molecular mechanisms underpinning glioblastoma invasion; however, there is no approved therapy directed against the invasive phenotype as of now. Here, we review the major molecular mechanisms of glioblastoma cell invasion, including the routes followed by glioblastoma cells, the interaction of tumor cells within the brain environment and the extracellular matrix components, and the roles of tumor cell adhesion and extracellular matrix remodeling. We also include a perspective of high-throughput approaches utilized to discover novel players for invasion and clinical targeting of invasive glioblastoma cells.

show abstract

“…BMI was calculated as weight (kg)/(height (m)) 2 , and the median values were 21.1 (15.5-29.2) for the bevacizumab group and 21.5 (15.9-33.8) for the non-bevacizumab group (P=0.64). No significant differences were found in chemotherapy cycles {6[6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] vs. 6 [6-16]; P=0.68}, baseline spleen sizes [152.2 (74.1-529.6) vs. 150.0 (69.5-410.8); P=0.11] (cm 3 ), and baseline platelet counts {162 [77-441] vs. 166 [69-532]; P=0.90} (K/μL) between the two groups.…”

mentioning

confidence: 94%

“…Bevacizumab enhances the effect of chemotherapy in colorectal cancer and was approved by the FDA as the first angiogenesis inhibitor to treat metastatic colorectal cancer (mCRC) (5). However, it has several adverse effects including hypertension, proteinuria, thromboembolic events, wound-healing complications, congestive heart failure, and gastrointestinal perforation (6)(7)(8)(9)(10)(11). Bevacizumab plus oxaliplatin-based chemotherapy and bevacizumab plus irinotecan-based chemotherapy are equally effective.…”

Section: Introductionmentioning

confidence: 99%

The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis

Zhou¹,

Feng²,

Zhang³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: The basic platelet counts of schistosomiasis patients are low. If it does not meet the requirements for chemotherapy, the patient's treatment will not be carried out, which directly affects their prognosis. Therefore the impact of treatment on platelet counts is critically important. The effects of bevacizumab plus oxaliplatin-based chemotherapy and bevacizumab plus irinotecan-based chemotherapy regimens on platelets are different but have not been determined. In order to find a more suitable plan for metastatic colorectal cancer (mCRC) patients with a history of schistosomiasis, we conducted a retrospective analysis of mCRC patients and evaluated the impact of bevacizumab on their platelets. Methods:The medical records of all mCRC patients with a history of schistosomiasis who received oxaliplatin-based chemotherapy or irinotecan-based chemotherapy as first-line treatment for no less than 4 cycles, with or without bevacizumab from September 1, 2017, to June 30, 2019, in Kunshan Hospital were reviewed. Six-month cumulative incidence rates of splenomegaly and thrombocytopenia of chemotherapy with and without bevacizumab groups, oxaliplatin-based chemotherapy with and without bevacizumab groups, irinotecan-based chemotherapy with and without bevacizumab groups were compared from the first cycle until the completion of chemotherapy using Kaplan-Meier analysis and Log-rank test.Results: Evaluable splenic enlargement and thrombocytopenia results were obtained from 153 mCRC patients. The 6-month cumulative incidence rates of splenomegaly (23.3% vs. 55%; P=0.01) and that of thrombocytopenia (43.8% vs. 57.5%; P=0.40) were lower in the bevacizumab group than the nonbevacizumab group, however there were no statistical differences for the rates of thrombocytopenia. For patients treated with oxaliplatin, the rates of splenomegaly (19.5% vs. 66.7%; P=0.01) and thrombocytopenia (31.7% vs. 77.2%; P=0.02) were lower in the bevacizumab-treated cohort than that in the non-bevacizumab cohort. When stratified for irinotecan, there were no statistical differences in the frequency of splenomegaly between the two groups. However, the rates of thrombocytopenia were higher in the bevacizumab-treated cohort than that in the non-bevacizumab cohort (59.4% vs. 8.7%; P=0.01). Conclusions:The bevacizumab plus oxaliplatin-based chemotherapy regimen is safer for mCRC patients with a history of schistosomiasis, especially for patients with a lower platelet count.

show abstract

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

Cited by 7 publications

References 40 publications

Oncolytic viral therapy as promising immunotherapy against glioma

Oncolytic viral therapy as promising immunotherapy against glioma

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis

Contact Info

Product

Resources

About